Ciliary neurotrophic factor protects striatal neurons against excitotoxicity by enhancing glial glutamate uptake

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Beurrier, Corinne ^a   Faideau, Mathilde ^a,b   Bennouar, Khaled Ezaheir ^a   Escartin, Carole ^a,b   Kerkerian Le Goff, Lydia ^a   Bonvento, Gilles ^a,b   Gubellini, Paolo ^a  

^a CNRS   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; GAMMA DEXTRO GLUTAMYLGLYCINE; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; QUINOLINIC ACID; ASPARTIC ACID; BENZYLOXYASPARTATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; ELECTRIC POTENTIAL; EXCITOTOXICITY; GLIA; IN VIVO STUDY; NEUROPROTECTION; NONHUMAN; PATCH CLAMP; RAT; ANIMAL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; EVOKED RESPONSE; IN VITRO STUDY; METABOLISM; NERVE CELL; PHYSIOLOGY;

ANIMALIA; RATTUS;

AMINO ACID TRANSPORT SYSTEM X-AG; ANIMALS; ASPARTIC ACID; CILIARY NEUROTROPHIC FACTOR; CORPUS STRIATUM; EVOKED POTENTIALS; GLUTAMIC ACID; NEURONS; QUINOLINIC ACID; RATS;

EID: 77649116866     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008550     Document Type: Article

References (39)

1. Sendtner M, Carroll P, Holtmann B, Hughes RA, Thoenen H (1994) Ciliary neurotrophic factor. J Neurobiol 25(11): 1436-1453.
2. Alberch J, Perez-Navarro E, Canals JM (2004) Neurotrophic factors in Huntington's disease. Prog Brain Res 146: 195-229.
3. Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59(5): 427-468.
4. Fan MM, Raymond LA (2007) N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 81(5-6): 272-293.
5. Anderson KD, Panayotatos N, Corcoran TL, Lindsay RM, Wiegand SJ (1996) Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc Natl Acad Sci U S A 93(14): 7346-7351.
6. Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen EY, et al. (1997) Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 386(6623): 395-399.
7. Mittoux V, Joseph JM, Conde F, Palfi S, Dautry C, et al. (2000) Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum Gene Ther 11(8): 1177-1187.
8. Bloch J, Bachoud-Levi AC, Deglon N, Lefaucheur JP, Winkel L, et al. (2004) Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 15(10): 968-975.
9. Winter CG, Saotome Y, Levison SW, Hirsh D (1995) A role for ciliary neurotrophic factor as an inducer of reactive gliosis, the glial response to central nervous system injury. Proc Natl Acad Sci U S A 92(13): 5865-5869.
10. Levison SW, Ducceschi MH, Young GM, Wood TL (1996) Acute exposure to CNTF in vivo induces multiple components of reactive gliosis. Exp Neurol 141(2): 256-268.
11. Lisovoski F, Akli S, Peltekian E, Vigne E, Haase G, et al. (1997) Phenotypic alteration of astrocytes induced by ciliary neurotrophic factor in the intact adult brain, As revealed by adenovirus-mediated gene transfer. J Neurosci 17(19): 7228-7236.
12. Escartin C, Brouillet E, Gubellini P, Trioulier Y, Jacquard C, et al. (2006) Ciliary neurotrophic factor activates astrocytes, redistributes their glutamate transporters GLAST and GLT-1 to raft microdomains, and improves glutamate handling in vivo. J Neurosci 26(22): 5978-5989.
13. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65(1): 1-105.
14. Escartin C, Pierre K, Colin A, Brouillet E, Delzescaux T, et al. (2007) Activation of astrocytes by CNTF induces metabolic plasticity and increases resistance to metabolic insults. J Neurosci 27(27): 7094-7104.
15. Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45(3): 309-379.
16. Connick JH, Stone TW (1988) Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo. Br J Pharmacol 93(4): 868-876.
17. Mallozzi C, Martire A, Domenici MR, Metere A, Popoli P, et al. (2007) LNAME reverses quinolinic acid-induced toxicity in rat corticostriatal slices: Involvement of src family kinases. J Neurosci Res 85(12): 2770-2777.
18. Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, et al. (2006) The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 51(5): 1004-1012.
19. Tebano MT, Domenici MR, Popoli P (2002) SCH 58261 differentially influences quinolinic acid-induced effects in striatal and in hippocampal slices. Eur J Pharmacol 450(3): 253-257.
20. Liu G, Choi S, Tsien RW (1999) Variability of neurotransmitter concentration and nonsaturation of postsynaptic AMPA receptors at synapses in hippocampal cultures and slices. Neuron 22(2): 395-409.
21. Oliet SH, Piet R, Poulain DA (2001) Control of glutamate clearance and synaptic efficacy by glial coverage of neurons. Science 292(5518): 923-926.
22. Beurrier C, Bonvento G, Kerkerian-Le GL, Gubellini P (2009) Role of glutamate transporters in corticostriatal synaptic transmission. Neuroscience 158(4): 1608-1615.
23. Emerich DF, Lindner MD, Winn SR, Chen EY, Frydel BR, et al. (1996) Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J Neurosci 16(16): 5168-5181.
24. Mittoux V, Ouary S, Monville C, Lisovoski F, Poyot T, et al. (2002) Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J Neurosci 22(11): 4478-4486.
25. Pereira de Almeida L, Zala D, Aebischer P, Deglon N (2001) Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis 8(3): 433-446.
26. Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, et al. (2002) Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 22(5): 1967-1975.
27. Orlando LR, Alsdorf SA, Penney JB Jr, Young AB (2001) The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity. Exp Neurol 167(1): 196-204.
28. Monville C, Coulpier M, Conti L, De-Fraja C, Dreyfus P, et al. (2001) Ciliary neurotrophic factor may activate mature astrocytes via binding with the leukemia inhibitory factor receptor. Mol Cell Neurosci 17(2): 373-384.
29. Kordower JH, Yaping C, Maclennan AJ (1997) Ciliary neurotrophic factor receptor alpha-immunoreactivity in the monkey central nervous system. J Comp Neurol 377(3): 365-380.
30. Mattson MP, Lovell MA, Furukawa K, Markesbery WR (1995) Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J Neurochem 65(4): 1740-1751.
31. Butchbach ME, Tian G, Guo H, Lin CL (2004) Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft micro-domains: importance for excitatory amino acid transporter localization and function. J Biol Chem 279(33): 34388-34396.
32. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L (1996) Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 40(5): 759-766.
33. Mathern GW, Mendoza D, Lozada A, Pretorius JK, Dehnes Y, et al. (1999) Hippocampal GABA and glutamate transporter immunoreactivity in patients with temporal lobe epilepsy. Neurology 52(3): 453-472.
34. Arzberger T, Krampfl K, Leimgruber S, Weindl A (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - an in situ hybridization study. J Neuropathol Exp Neurol 56(4): 440-454.
35. Lievens JC, Dutertre M, Forni C, Salin P, Kerkerian-Le GL (1997) Continuous administration of the glutamate uptake inhibitor L-trans-pyrrolidine- 2,4-dicarboxylate produces striatal lesion. Brain Res Mol Brain Res 50(1-2): 181-189.
36. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB (2002) Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125(Pt 8): 1908-1922.
37. Hottinger AF, Azzouz M, Deglon N, Aebischer P, Zurn AD (2000) Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci 20(15): 5587-5593.
38. Coggeshall RE (1992) A consideration of neural counting methods. Trends Neurosci 15(1): 9-13.
39. Beurrier C, Malenka RC (2002) Enhanced inhibition of synaptic transmission by dopamine in the nucleus accumbens during behavioral sensitization to cocaine. J Neurosci 22(14): 5817-5822.